Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More

Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet